3 news items
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
NUVL
16 May 24
-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
NUVL
9 May 24
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
NUVL
8 Apr 24
statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express
- Prev
- 1
- Next